Impaired antioxidant activity of high-density lipoprotein in chronic kidney disease (Q46160198)

20 December 2017

title

Impaired antioxidant activity of high-density lipoprotein in chronic kidney disease (English)

1 reference

20 December 2017

1 reference

4

Nosratola D Vaziri

1 reference

20 December 2017

author name string

Hamid Moradi

series ordinal

1

1 reference

20 December 2017

Madeleine V Pahl

series ordinal

2

1 reference

20 December 2017

Reza Elahimehr

series ordinal

3

1 reference

20 December 2017

publication date

10 December 2008

1 reference

20 December 2017

published in

Translational Research

1 reference

20 December 2017

volume

153

1 reference

20 December 2017

page(s)

77-85

1 reference

20 December 2017

issue

2

1 reference

20 December 2017

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.007

Association of kidney function with mortality in patients with chronic kidney disease not yet on dialysis: a historical prospective cohort study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.007

Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.007

Effect of chronic renal failure on nitric oxide metabolism.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.007

Oxidative stress in uremia: nature, mechanisms, and potential consequences

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.007

The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.007

Why is chronic kidney disease the "spoiler" for cardiovascular outcomes?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.007

Inflammation in end-stage renal disease: sources, consequences, and therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.007

Inflammation and atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.007

The molecular basis of vulnerable plaque: potential therapeutic role for immunomodulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.007

Macrophage differentiation to foam cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.007

Monocyte recruitment and foam cell formation in atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.007

The induction of macrophage foam cell formation by chylomicron remnants.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.007

Effects of native and modified low-density lipoproteins on monocyte recruitment in atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.007

High-density lipoprotein metabolism: potential therapeutic targets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.007

Endothelial protection by high-density lipoproteins: from bench to bedside

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.007

Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.007

Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.007

Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.007

Atheroprotective effects of HDL: beyond reverse cholesterol transport.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.007

Serum apolipoprotein profile of patients with chronic renal failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.007

Lipid and apolipoprotein profiles of uremic dyslipoproteinemia--relation to renal function and dialysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.007

The prevalence of nontraditional risk factors for coronary heart disease in patients with chronic kidney disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.007

Effect of serum subfractions from peritoneal dialysis patients on Hep-G2 cell apolipoprotein A-I and B metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.007

Hepatic HDL receptor, SR-B1 and Apo A-I expression in chronic renal failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.007

Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.007

HDL-inflammatory index correlates with poor outcome in hemodialysis patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.007

HDL composition and HDL antioxidant capacity in patients on regular haemodialysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.007

Down-regulation of hepatic lecithin:cholesterol acyltransferase gene expression in chronic renal failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.007

ACAT inhibition reverses LCAT deficiency and improves plasma HDL in chronic renal failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.007

Lecithin: cholesterol acyltransferase activity in dialyzed and undialyzed chronic uremic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.007

Hyperlipidemia in chronic kidney disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.007

Antisense to LOX-1 inhibits oxidized LDL-mediated upregulation of monocyte chemoattractant protein-1 and monocyte adhesion to human coronary artery endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.007

Upregulation of endothelial receptor for oxidized LDL (LOX-1) by oxidized LDL and implications in apoptosis of human coronary artery endothelial cells: evidence from use of antisense LOX-1 mRNA and chemical inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.007

The binding of oxidized low density lipoprotein (ox-LDL) to ox-LDL receptor-1 reduces the intracellular concentration of nitric oxide in endothelial cells through an increased production of superoxide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.007

Oxidized low density lipoprotein (ox-LDL) binding to ox-LDL receptor-1 in endothelial cells induces the activation of NF-kappaB through an increased production of intracellular reactive oxygen species

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.007

Lectin-like, oxidized low-density lipoprotein receptor-1 (LOX-1): a critical player in the development of atherosclerosis and related disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.007

LOX-1, the receptor for oxidized low-density lipoprotein identified from endothelial cells: implications in endothelial dysfunction and atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.007

Expression of lectinlike oxidized low-density lipoprotein receptor-1 in human atherosclerotic lesions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.007

Cellular cholesterol substrate pools for adenosine-triphosphate cassette transporter A1-dependent high-density lipoprotein formation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.007

Disorders in high-density metabolism with insulin resistance and chronic kidney disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.007

High density lipoprotein is the major carrier of lipid hydroperoxides in human blood plasma from fasting donors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.007

Oxidized phospholipids: emerging lipid mediators in pathophysiology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.007

Inflammation and metabolic disorders.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.007

Low apolipoprotein A-I level at intensive care unit admission and systemic inflammatory response syndrome exacerbation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.007

Lipopolysaccharide (LPS)-binding protein is carried on lipoproteins and acts as a cofactor in the neutralization of LPS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.007

Biophysical characterization of the interaction of high-density lipoprotein (HDL) with endotoxins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.007

Reconstituted high-density lipoprotein attenuates organ injury and adhesion molecule expression in a rodent model of endotoxic shock

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.007

Mechanisms of disease: proatherogenic HDL--an evolving field

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.007

Understanding changes in high density lipoproteins during the acute phase response.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.007

Lipoprotein inflammatory properties and serum amyloid A levels but not cholesterol levels predict lesion area in cholesterol-fed rabbits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.007

Intra-renal angiotensin II/AT1 receptor, oxidative stress, inflammation, and progressive injury in renal mass reduction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.007

Oxidative stress in hemodialysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.007

Down-regulation of tissue lipoprotein lipase expression in experimental chronic renal failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.007

10.1016/J.TRSL.2008.11.007

7 January 2021

Identifiers

DOI

1 reference

20 December 2017

release_5h5rgfzzarcehoi6jg5s43sqmm

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/5h5rgfzzarcehoi6jg5s43sqmm

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

19138652

1 reference

20 December 2017